相似文献
1
Liquid biopsies for liquid tumors: emerging potential of circulating free nucleic acid evaluation for the management of hematologic malignancies.
Cancer Biol Med. 2016 Jun;13(2):215-25. doi: 10.20892/j.issn.2095-3941.2016.0025.
2
Integrated analysis of circulating cell free nucleic acids for cancer genotyping and immune phenotyping of tumor microenvironment.
Front Genet. 2023 Apr 6;14:1138625. doi: 10.3389/fgene.2023.1138625. eCollection 2023.
3
[Potential of Cell-free Circulating DNA in Diagnosis of Cancer].
Klin Onkol. 2015;28(4):251-9. doi: 10.14735/amko2015251.
4
Liquid biopsy: a step forward towards precision medicine in urologic malignancies.
Mol Cancer. 2017 Apr 14;16(1):80. doi: 10.1186/s12943-017-0644-5.
5
Evaluation of commercial kits for purification of circulating free DNA.
Cancer Genet. 2018 Dec;228-229:21-27. doi: 10.1016/j.cancergen.2018.08.005. Epub 2018 Aug 29.
6
Circulating nucleic acids: An analysis of their occurrence in malignancies.
Biomed Rep. 2017 Jan;6(1):8-14. doi: 10.3892/br.2016.812. Epub 2016 Nov 16.
7
Circulating cell-free DNA and circulating tumor cells, the "liquid biopsies" in ovarian cancer.
J Ovarian Res. 2017 Nov 13;10(1):75. doi: 10.1186/s13048-017-0369-5.
8
Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.
Oncologist. 2016 Sep;21(9):1121-30. doi: 10.1634/theoncologist.2016-0082. Epub 2016 Jul 7.
9
[Progress of study on circulating microRNAs in hematologic malignancies].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Feb;22(1):219-22. doi: 10.7534/j.issn.1009-2137.2014.01.043.
10
Circulating Tumour Cells, Cell Free DNA and Tumour-Educated Platelets as Reliable Prognostic and Management Biomarkers for the Liquid Biopsy in Multiple Myeloma.
Cancers (Basel). 2022 Aug 26;14(17):4136. doi: 10.3390/cancers14174136.
引用本文的文献
1
A case of T-cell acute lymphoblastic leukemia in retroviral gene therapy for ADA-SCID.
Nat Commun. 2024 Apr 30;15(1):3662. doi: 10.1038/s41467-024-47866-5.
2
Liquid biopsy in NSCLC: a new challenge in radiation therapy.
Explor Target Antitumor Ther. 2021;2(2):156-173. doi: 10.37349/etat.2021.00038. Epub 2021 Apr 30.
3
Controversies in the Interpretation of Liquid Biopsy Data in Lymphoma.
Hemasphere. 2022 May 13;6(6):e727. doi: 10.1097/HS9.0000000000000727. eCollection 2022 Jun.
4
Liquid biopsies in myeloid malignancies.
Cancer Drug Resist. 2019 Dec 19;2(4):1044-1061. doi: 10.20517/cdr.2019.88. eCollection 2019.
5
Longitudinal Monitoring of Plasma Circulating Tumour DNA Enables the Prediction of Early Relapse in Patients with Non-Hodgkin Lymphoma: A Case Series.
Diagnostics (Basel). 2021 Nov 5;11(11):2055. doi: 10.3390/diagnostics11112055.
6
Clinical Proteomics of Biofluids in Haematological Malignancies.
Int J Mol Sci. 2021 Jul 27;22(15):8021. doi: 10.3390/ijms22158021.
7
Recent Advances in the Use of Molecular Analyses to Inform the Diagnosis and Prognosis of Patients with Polycythaemia Vera.
Int J Mol Sci. 2021 May 10;22(9):5042. doi: 10.3390/ijms22095042.
8
Human Plasma Extracellular Vesicle Isolation and Proteomic Characterization for the Optimization of Liquid Biopsy in Multiple Myeloma.
Methods Mol Biol. 2021;2261:151-191. doi: 10.1007/978-1-0716-1186-9_10.
9
Hunting down the dominating subclone of cancer stem cells as a potential new therapeutic target in multiple myeloma: An artificial intelligence perspective.
World J Stem Cells. 2020 Aug 26;12(8):706-720. doi: 10.4252/wjsc.v12.i8.706.
10
Multiplex bioimaging of single-cell spatial profiles for precision cancer diagnostics and therapeutics.
NPJ Precis Oncol. 2020 May 1;4:11. doi: 10.1038/s41698-020-0114-1. eCollection 2020.
本文引用的文献
1
Circulating microRNA Biomarkers as Liquid Biopsy for Cancer Patients: Pros and Cons of Current Assays.
J Clin Med. 2015 Oct 23;4(10):1890-907. doi: 10.3390/jcm4101890.
2
Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression.
J Mol Diagn. 2015 Nov;17(6):669-78. doi: 10.1016/j.jmoldx.2015.06.006. Epub 2015 Sep 30.
3
The impact of standard chemotherapy on miRNA signature in plasma in AML patients.
Leuk Res. 2015 Dec;39(12):1389-95. doi: 10.1016/j.leukres.2015.08.009. Epub 2015 Aug 20.
4
DREAMing: a simple and ultrasensitive method for assessing intratumor epigenetic heterogeneity directly from liquid biopsies.
Nucleic Acids Res. 2015 Dec 15;43(22):e154. doi: 10.1093/nar/gkv795. Epub 2015 Aug 24.
5
Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia.
Blood. 2015 Jul 23;126(4):445-53. doi: 10.1182/blood-2015-02-585042. Epub 2015 Jun 11.
6
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.
Blood. 2015 Jun 11;125(24):3679-87. doi: 10.1182/blood-2015-03-635169. Epub 2015 Apr 17.
7
Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study.
Lancet Oncol. 2015 May;16(5):541-9. doi: 10.1016/S1470-2045(15)70106-3. Epub 2015 Apr 1.
8
Digital PCR analysis of circulating nucleic acids.
Clin Biochem. 2015 Oct;48(15):948-56. doi: 10.1016/j.clinbiochem.2015.03.015. Epub 2015 Mar 28.
9
Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis.
Haematologica. 2015 Jul;100(7):e280-4. doi: 10.3324/haematol.2015.123612. Epub 2015 Mar 6.
10
A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma.
Oncotarget. 2015 Jan 30;6(3):1874-83. doi: 10.18632/oncotarget.2761.
Zotero 插件